In order to bolster its late-stage oncology portfolio, Jazz Pharmaceuticals has signed a licensing agreement with Zymeworks for the development and commercialisation of zanidatamab, a HER2-targeted bispecific antibody. Jazz will pay Zymeworks US$50 M upfront to obtain development and commercialisation rights to zanidatamab for all indications in US, Europe, Japan, and all other territories excluding Asia/Pacific territories previously licensed to BeiGene. Zymeworks is also eligible to receive an additional US$325 M payment if Jazz decides to continue the collaboration following Phase II data read out from HERIZON-BTC-01 study in biliary tract cancer (BTC).